CN117757758B - Natural attenuated strain of infectious laryngotracheitis virus with good safety and immunogenicity and application thereof - Google Patents
Natural attenuated strain of infectious laryngotracheitis virus with good safety and immunogenicity and application thereofInfo
- Publication number
- CN117757758B CN117757758B CN202311854854.1A CN202311854854A CN117757758B CN 117757758 B CN117757758 B CN 117757758B CN 202311854854 A CN202311854854 A CN 202311854854A CN 117757758 B CN117757758 B CN 117757758B
- Authority
- CN
- China
- Prior art keywords
- infectious laryngotracheitis
- virus
- strain
- vaccine
- iltv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/91—Cell lines ; Processes using cell lines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a natural attenuated strain of infectious laryngotracheitis virus with good safety and immunogenicity. The strain is named as infectious laryngotracheitis virus ILTV FJ19, and is preserved in China Center for Type Culture Collection (CCTCC) with the preservation number of V2023109 in 11-29 of 2013. Experiments show that the chicken infectious laryngotracheitis virus ILTV FJ19 strain has stable passage capability, can be suitable for allantoic cavity way inoculation, has good safety and immunogenicity when being inoculated to 14-day-old SPF chickens, can be used for immunization through eye injection or oral administration, and can be used as a attenuated live vaccine candidate strain of the ILTV.
Description
Technical Field
The invention relates to the separation and identification of natural attenuated strain of infectious laryngotracheitis virus, and the determination of immunogenicity and safety of the strain as live vaccine, belonging to the technical field of microorganism. The strain is obtained by separating a domestic chicken group in a conventional pathogen monitoring process, is named as ILTV FJ19 strain after separation, identification, purification and cloning, is used for measuring the safety of 14-day-old SPF chicken, and is used for measuring the immunogenicity of 14-day-old SPF chicken by challenge of WF03 strain (patent strain, patent number: ZL202110385416. X) after 21 days of immunization. The determination result shows that the infectious laryngotracheitis virus ILTV FJ19 strain has good safety and immunogenicity, and can be used as an ILTV attenuated live vaccine candidate strain.
Background
Infectious laryngotracheitis virus (ILTV) belongs to the genus infectious laryngotracheitis virus of the subfamily herpesviridae and the subfamily alphaherpesviridae, the infection mainly causes death and/or egg laying drop of chickens, serious infection often appears as dyspnea, wheezing and coughing of blood sample liquid, the infection has high lethality, mild infection mainly appears as multiple forms of mucositis, rhinitis, conjunctivitis, unwilling activity, low mortality and the like, and serious loss and threat are brought to production for both serious infection and mild infection.
The genome of ILTV is about 155Kbp in size and is a double stranded DNA virus, and like other herpesviruses, the genome includes structures such as a long unique region, a short unique region, and inverted repeats at both ends, encoding a large number of glycoproteins and proteins associated with virulence and viral replication. The ILTV wild strains have great toxicity difference, and part of the strains have high morbidity and mortality after infecting chickens, belong to the strains with strong pathogenicity, and the strains with slight or no obvious symptoms and no mortality after infecting belong to the strains with weak strains.
The attenuated live vaccine is a main vaccine type for preventing animal infectious diseases, but most of the current poultry vaccine strains are attenuated through avian embryo or cell passage, the attenuated strain for preparing the vaccine obtained in the mode has uncertainty of virulence return of the strain, and the natural attenuated strain has the advantages of low toxicity, small side effect, good immunogenicity and the like.
Disclosure of Invention
The invention aims to provide a natural attenuated strain of infectious laryngotracheitis virus with good safety and immunogenicity.
The technical scheme adopted by the invention is as follows:
A natural attenuated strain of infectious laryngotracheitis virus with good safety and immunogenicity is named as infectious laryngotracheitis virus ILTV FJ19, and is classified as infectious laryngotracheitis virus (infectious laryngotracheitis virus) which is preserved in China Center for Type Culture Collection (CCTCC) No. V2023109 and has a preservation address of university of Wuhan, china at 2023, 11 months and 29 days.
The natural attenuated strain of the infectious laryngotracheitis virus is applied to the preparation of vaccines, wherein the vaccines are attenuated live vaccines, the attenuated live vaccines are used for preventing infectious laryngotracheitis, and the infectious laryngotracheitis is avian infectious laryngotracheitis.
The infectious laryngotracheitis vaccine contains live viruses of natural attenuated strains of the infectious laryngotracheitis viruses, wherein the immunization mode of the infectious laryngotracheitis vaccine comprises an oral administration or eye-spot immunization way, and the infectious laryngotracheitis vaccine is used for immunizing chickens, and the immune protection rate of the infectious laryngotracheitis vaccine after 21 days of immunization is 100% after the infectious laryngotracheitis vaccine is subjected to ILTV virulent WF03 strain (patent strain, patent number ZL202110385416. X).
The preparation method of the infectious laryngotracheitis vaccine comprises the steps of taking a natural attenuated strain of the infectious laryngotracheitis virus as a vaccine production strain, inoculating SPF chick embryos through an allantoic cavity way, harvesting infected embryo bodies and/or allantoic membranes, and grinding to prepare a virus solution, thus obtaining the infectious laryngotracheitis vaccine.
The invention has the remarkable advantages that:
The invention purifies and clones a strain of ILTV virus which is genetically stable and can adapt to the inoculation of chick embryo allantoic cavity approach by pathogen separation and identification of the conventional chicken flock, and is named FJ19 strain. The ILTV FJ19 strain P1 generation culture is used for inoculating 14-day-old SPF chickens, so that the SPF chickens have good safety and have good immune protection after being challenged by WF03 strain. The virus culture inoculated by the allantoic cavity way of ILTV FJ19 strain has good safety when being inoculated to SPF chicken of 14 days old, and has good immune protection after being challenged by WF03 strain. Therefore, the isolated and cloned ILTV FJ19 strain has stable passage capability, can adapt to allantoic cavity way inoculation, has good safety and immunogenicity when being inoculated to 14-day-old SPF chickens, can be used for immunization through eye-drop or oral administration, and can be used as a attenuated live vaccine candidate strain of the ILTV.
Drawings
FIG. 1, allantoic pathology and off-white spots of 10-day-old SPF chick embryos inoculated by the allantoic route for suspected ILTV virus 7 days later.
Detailed Description
In order to make the contents of the present invention more easily understood, the technical scheme of the present invention will be further described with reference to the specific embodiments, but the present invention is not limited thereto.
EXAMPLE 1 isolation, identification and purification of strains clones
In the conventional pathogen monitoring process of chicken flocks, PBS (0.01M, pH 7.2-7.4) is added into tissues of suspected ILTV infection positive samples in a ratio of 1:5m/v, the tissues are ground and frozen and thawed for 3 times, the solution is centrifuged for 10min by 12000r/min and then filtered by a 0.45 mu m filter membrane, the filtrate is inoculated with SPF chick embryos of 10 days old by an allantoic membrane way and then is hatched for 7d, the allantoic membrane is aseptically harvested, PBS (0.01M, pH 7.2-7.4) is added into the solution in a ratio of 1:5m/v, the tissues are ground and thawed for 3 times, and the supernatant is centrifuged and taken to be inoculated with SPF chick embryos of 10 days old by the allantoic membrane way and then passaged for 2 times, and then the pathological changes of the chick embryos are observed. The chick embryo allantois found to exhibit off-white spots (figure 1) after 3 generations of blind transmission, suspected ILTV virus infection, and is identified as ILTV virus according to the agricultural industry standard NY/T556-2020 chicken infectious laryngotracheitis diagnosis technology.
The identified ILTV virus strain is inoculated into 10-day-old chick embryos by an allantoic membrane way for purification and cloning by adopting a limiting dilution method, 10 times of virus liquid is serially diluted, 10 -2、10-3、10-4、10-5、10-6 dilutions are inoculated into 10-day-old SPF chick embryos, 6 dilutions are inoculated, the allantoic membrane is checked after the incubation is continued for 7 days, the allantoic membrane is judged to be positive when grey and white spots appear on the allantoic membrane, the positive allantoic membrane with the highest dilution is ground to prepare the virus liquid, and the purification and cloning are continued for 4 times by adopting the same method. Two ILTV viruses cloned by purification were designated FJ19 and FJ22 strains, respectively, and allantoic membrane preparation virus was obtained by expanding culture in SPF chick embryos of 10 days old, and was designated as P1 generation.
Taking out the preserved virus liquid from the temperature of-70 ℃, melting and balancing to room temperature, respectively taking 0.5mL, adding the solution into corresponding 4.5mL PBS (0.01M, pH 7.2-7.4), sequentially diluting the solution to 10 -6 by 10 times, respectively inoculating 6 SPF chick embryos of 10 days old to each dilution of the virus liquid, taking 6 chick embryos as negative control, putting the chick embryos into a 37 ℃ incubator for continuous incubation for 7 days, marking the gray color spots on the allantoic membrane as positive, and calculating the ILTV virus content to be 10 5.70EID50/mL according to a Reed-Muench method according to the positive number.
EXAMPLE 2 culture Properties of ILTV FJ19 strain and FJ22 strain
The culture of ILTV FJ19 strain and FJ22 strain is carried out on SPF chick embryo of 10 days old, the harvested P1 generation is inoculated by allantoic membrane route, the virus content in virus liquid prepared by harvesting allantoic membrane is highest, and after 7 days of inoculation of chick embryo, the allantoic membrane has massive grey white focus or a great number of grey white spots. The obtained virus liquid is detected according to the detection method of no bacteria, no mycoplasma and no exogenous virus in Chinese animal pharmacopoeia (2020 edition), and the result shows that the virus liquid of the ILTV FJ19 strain and the FJ22 strain has no bacteria, no mycoplasma and no exogenous virus pollution and is pure ILTV virus.
EXAMPLE 3 immunogenicity determination of ILTV FJ19 and FJ22 strains
The 60-feather 14-day-old SPF chickens were divided into 6 groups, namely G1, G2, G3, G4, G5 and G6 groups, wherein the G1 and G2 groups were not vaccinated, the G3 and G4 groups were vaccinated with ILTV FJ19 clone virus (generation P1) by eye-on and oral administration, and the G5 and G6 groups were vaccinated with ILTV FJ22 clone virus (generation P1) by eye-on and oral administration, at doses of 10 3.0EID50 per feather chicken, and 21 days after vaccination were continuously observed. After 21 days, the G2, G3, G4, G5 and G6 groups were subjected to tracheal challenge with the virulent strain ILTVWF, the challenge amount was 0.2 mL/feather, the virus content was 10 4.0EID50, the G1 group was not subjected to challenge as a negative control group, and clinical symptoms were continuously observed 14 days after challenge.
The results showed that within 21 days after immunization, the chickens in the vaccinated group had no visible side effects such as lacrimation, ophthalmia, and respiratory tract reaction, and within 14 days of observation period after challenge, the chickens in the G1 group had no visible specific clinical symptoms, the chickens in the G2 group had 100% (10/10), the mortality 40% (4/10), the specific clinical symptoms such as hemoptysis and open breath, the chickens in the G3 group (ILTV FJ19 spot eye inoculation group) and the chickens in the G4 group (ILTV FJ19 oral inoculation group) had 0% (0/10), the mortality 0% (0/10), the specific clinical symptoms were not seen, the chickens in the G5 group (ILTV FJ22 spot eye inoculation group) had 60% (6/10), the mortality 30% (3/10), the specific clinical symptoms such as hemoptysis and open breath, the morbidity in the G6 group (ILTV FJ22 oral inoculation group) had 70% (7/10), the mortality 30% (3/10), and the specific clinical symptoms such as hemoptysis and open breath. The result shows that the ILTV FJ19 clone has good virus immunogenicity, can be used as a vaccine immunization strain, and has poor virus attack protection effect after the ILTV FJ22 is immunized on chicken, and is not suitable for being used as a vaccine candidate strain.
EXAMPLE 4 safety assay of ILTV FJ19 Strain
30-Feather 14-day-old SPF chickens are divided into 3 groups, namely G1, G2 and G3, wherein the G1 group is not inoculated with immunity, G2 is inoculated with ILTV FJ19 cloned virus (P1 generation) in an eye-drop manner, the inoculation dose is 10 4.0EID50 per feather chicken, G3 is inoculated with ILTV FJ19 cloned virus (P1 generation) in an eye-drop manner, the inoculation dose is 10 5.0EID50 per feather chicken, and continuous observation is carried out for 14 days after inoculation.
The results show that within 14 days after inoculation, the G1 group of chickens have no visible clinical symptoms, the G2 group of chickens have no visible side effects such as lacrimation, ophthalmia and respiratory tract reaction, and 20% of chickens immunized by the G3 group of chickens have visible transient side effects such as lacrimation, ophthalmia and the like 4-6 days after inoculation.
Example 5 safety and immunogenicity determination of ILTV FJ19 Strain after adaptation by allantoic cavity route virus of the P1 generation of ILTV FJ19 strain was continuously inoculated by allantoic cavity route to SPF chick embryo of 10 days old, allantoic membrane and embryo body or mixture of allantoic membrane and embryo body were harvested after 5-7 days incubation, respectively, packaged and preserved after grinding with appropriate amount of PBS (0.01M, pH 7.2-7.4), and EID 50 was measured, and the allantoic cavity inoculation passaging was performed to prepare virus solutions of different generations to obtain virus solutions of P2, P3, P4 generation to P7 generation.
The 50 feather 14 day-old SPF chickens are divided into 5 groups which are respectively G1, G2, G3, G4 and G5, wherein the G1 group is not inoculated with immunity, the G2 group and the G3 group are respectively inoculated with allantoic membrane toxin and embryoid body toxin of P5 generation ILTV FJ19 clone harvested after being inoculated and adapted by an allantoic cavity way in an eye-spot mode, the G4 group and the G5 group are respectively inoculated with allantoic membrane toxin and embryoid body toxin of P7 generation FJ19 clone harvested after being inoculated and adapted by the allantoic cavity way in an eye-spot mode, the inoculation dose is 10 4.0EID50 per feather chicken, and the continuous observation is carried out for 14 days after being inoculated.
The results show that within 14 days after immunization, the chickens in the group G1 do not have any visible clinical symptoms, and the chickens immunized by the groups G2, G3, G4 and G5 do not have visible side effects such as lacrimation, ophthalmia, respiratory tract reaction and the like.
The 60 feather 14 day-old SPF chickens are divided into 6 groups, namely G1, G2, G3, G4, G5 and G6, wherein the G1 group and the G2 group are not inoculated with immunity, the G3 group and the G4 group are respectively inoculated with allantoic membrane toxin and embryoid body toxin of P5 generation FJ19 clone harvested after being inoculated and adapted by allantoic cavity route in a point eye way, the G5 group and the G6 group are respectively inoculated with allantoic membrane toxin and embryoid body toxin of P7 generation FJ19 clone harvested after being inoculated and adapted by allantoic cavity route in a point eye way, the inoculation dosages are 10 3.0EID50 per feather chicken, after 21 days of inoculation, the G2 group, the G3 group, the G4 group, the G5 group and the G6 group are subjected to tracheal challenge with virulent strain ILTVWF03, the toxin amount is 0.2 mL/feather, the virus content is 10 4.0EID50, the G1 group 10 feather is not attacked as a negative control group, and clinical symptoms are observed for 14 days continuously after the challenge.
The results show that within the 14 days observation period after the challenge, the specific clinical symptoms are not observed in the chickens in the group G1, the morbidity of the chickens in the group G2 is 100% (10/10), the mortality is 40% (4/10), the specific clinical symptoms such as hemoptysis, open mouth respiration and the like are shown, the morbidity of the chickens in the group G3 (P5 allantoic viruses) and the chickens in the group G4 (P5 embryoid bodies) are 0% (0/10), the mortality is 0% (0/10), the specific clinical symptoms are not seen, the morbidity of the chickens in the group G5 (P7 allantoic viruses) and the chickens in the group G6 (P7 embryoid bodies) are 0% (0/10), the mortality is 0% (0/10), and the specific clinical symptoms are not seen.
EXAMPLE 6 sequencing of major immunogenic and virulence genes of the ILTV FJ19 Strain
PCR amplification, cloning and sequencing were performed on genes gE/gI, TK, ICP4, gC, gG, immunogenic genes gB, UL32, gD, gC, and virus replication-related gene gB, gD, gE, gI, gH, gL, gK, gM, gN, respectively, of ILTV FJ19 strain P1 generation virus solution, which are genomic templates involved in virulence, using the primers in Table 1.
The amplification system is as follows:
TABLE 1 primer names and sequences used for PCR amplification
The recovered PCR product was ligated into blunt end vector (pClone 007 Blunt Simple Vector Kit, optimus, praeparata) and competent cells DH 5. Alpha. Were transformed and coated with ampicillin-containing plates, 5 clones (bacterial liquid) of each gene are screened and sent to a biological engineering (Shanghai) stock company for sequencing, and upstream and downstream redundant sequences of a target gene sequence in the sequencing sequence are deleted and analyzed and compared. The sequence information of ILTV FJ19 virus gK, gG, gE, UL, ICP4 and gC, gL, gN, TK, gM, gD, gB, gH, gI genes is shown in SEQ ID NO. 1-14 respectively. ILTV FJ19 virus gene sequences differ to a different extent from the domestic and foreign attenuated strains A20 (NCBI accession number: JN 596963), K317 (NCBI accession number: JX 458824), LT Blen (NCBI accession number: JQ 083493), laryngo Vac (NCBI accession number: JQ 083494), poulvac ILT (R) (NCBI accession number: KP 677882), rus/Ck/TATARSTAN/2009/1643 (NCBI accession number: MF 405079), nobilis Laringovac (R) (NCBI accession number: KP 677881).
EXAMPLE 7 determination of the immune duration of ILTV FJ19 Strain
The SPF chickens with 70 feathers and 14 days of age are divided into 2 groups, one group is 30 feathers, the virus (P1 generation) of FJ19 clones is inoculated in an eye-drop mode, the inoculation dose is 10 3.0EID50 per feather chicken, and the other group is 40 feathers and is not immunized. At 4, 5 and 6 months after immunization, two groups respectively take 10 feather chickens to carry out tracheal detoxification by using a virulent strain ILTVWF strain 03, the toxin attacking amount is 0.2 mL/feather, the virus content is 10 4.0EID50, and clinical symptoms are continuously observed 14 days after the toxin attacking.
The results show that the incidence of the non-challenged chickens in the observation period after the challenge is 100% (10/10), 100% (10/10) and 90% (9/10) respectively in the observation period after the challenge, and the incidence of the immunized chickens in the observation period after the challenge is 0% (0/10), 0% (0/10) and 10% (1/10) respectively in the observation period after the challenge, wherein the incidence of the non-challenged chickens is expressed by specific clinical symptoms such as hemoptysis, open breath and the like in the observation period after the challenge, and the incidence of the immunized chickens is 0% (0/10).
The foregoing description is only of the preferred embodiments of the invention, and all changes and modifications that come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
Claims (8)
1. A natural attenuated strain of infectious laryngotracheitis virus is characterized in that the strain is named as infectious laryngotracheitis virus (infectious laryngotracheitis virus) ILTV FJ19, and is preserved in China Center for Type Culture Collection (CCTCC) No. V2023109 in 2023, 11 and 29 days.
2. Use of a natural attenuated strain of infectious laryngotracheitis virus as defined in claim 1, in the preparation of a live vaccine for preventing infectious laryngotracheitis.
3. The method according to claim 2, wherein the live vaccine is a naturally attenuated live vaccine.
4. The method according to claim 2, wherein said infectious laryngotracheitis is avian infectious laryngotracheitis.
5. An infectious laryngotracheitis vaccine, wherein the infectious laryngotracheitis vaccine is characterized by comprising a live virus of a natural attenuated strain of infectious laryngotracheitis virus as defined in claim 1.
6. The infectious laryngotracheitis vaccine according to claim 5, wherein the immunization regimen of the infectious laryngotracheitis vaccine comprises oral immunization or spot eye immunization.
7. The infectious laryngotracheitis vaccine as set forth in claim 5, wherein the live virus is obtained by inoculating the natural attenuated strain of infectious laryngotracheitis virus with SPF chick embryo via allantoic cavity for 5-7 days, and harvesting allantoic membrane and/or embryo body.
8. A preparation method of an infectious laryngotracheitis vaccine is characterized in that the natural attenuated strain of the infectious laryngotracheitis virus as the vaccine production strain is used, SPF chick embryos are inoculated through an allantoic cavity way, and infectious embryo bodies and/or allantoic membranes are harvested and ground after 5-7 days to prepare a virus solution, so that the infectious laryngotracheitis vaccine is obtained.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311854854.1A CN117757758B (en) | 2023-12-29 | 2023-12-29 | Natural attenuated strain of infectious laryngotracheitis virus with good safety and immunogenicity and application thereof |
| PCT/CN2024/102158 WO2025138665A1 (en) | 2023-12-29 | 2024-06-28 | Natural attenuated strain of infectious laryngotracheitis virus with good safety and good immunogenicity and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311854854.1A CN117757758B (en) | 2023-12-29 | 2023-12-29 | Natural attenuated strain of infectious laryngotracheitis virus with good safety and immunogenicity and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117757758A CN117757758A (en) | 2024-03-26 |
| CN117757758B true CN117757758B (en) | 2025-11-07 |
Family
ID=90325621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311854854.1A Active CN117757758B (en) | 2023-12-29 | 2023-12-29 | Natural attenuated strain of infectious laryngotracheitis virus with good safety and immunogenicity and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN117757758B (en) |
| WO (1) | WO2025138665A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117757758B (en) * | 2023-12-29 | 2025-11-07 | 福建省农业科学院畜牧兽医研究所 | Natural attenuated strain of infectious laryngotracheitis virus with good safety and immunogenicity and application thereof |
| CN120118857A (en) * | 2025-03-10 | 2025-06-10 | 中国兽医药品监察所 | Establishment of a virulent strain of infectious laryngotracheitis virus, a challenge model and a method for evaluating vaccine efficacy |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113652406A (en) * | 2021-09-01 | 2021-11-16 | 青岛易邦生物工程有限公司 | Recombinant virus strain for avian infectious laryngotracheitis and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002356441A (en) * | 2001-03-15 | 2002-12-13 | Akzo Nobel Nv | Recombinant infectious laryngotracheitis virus vaccine |
| CN103055311B (en) * | 2012-12-28 | 2014-05-21 | 中山大学 | A kind of infectious laryngotracheitis mucosal vaccine and its preparation method and application |
| US10201604B2 (en) * | 2013-10-29 | 2019-02-12 | University Of Delaware | Live attenuated infectious laryngotracheitis virus (ILTV) vaccines and preparation thereof |
| CN113122509B (en) * | 2021-04-10 | 2022-09-27 | 福建省农业科学院畜牧兽医研究所 | Infectious laryngotracheitis virus virulent strain and application thereof |
| CN117757758B (en) * | 2023-12-29 | 2025-11-07 | 福建省农业科学院畜牧兽医研究所 | Natural attenuated strain of infectious laryngotracheitis virus with good safety and immunogenicity and application thereof |
-
2023
- 2023-12-29 CN CN202311854854.1A patent/CN117757758B/en active Active
-
2024
- 2024-06-28 WO PCT/CN2024/102158 patent/WO2025138665A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113652406A (en) * | 2021-09-01 | 2021-11-16 | 青岛易邦生物工程有限公司 | Recombinant virus strain for avian infectious laryngotracheitis and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2025138665A1 (en) | 2025-07-03 |
| CN117757758A (en) | 2024-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117757758B (en) | Natural attenuated strain of infectious laryngotracheitis virus with good safety and immunogenicity and application thereof | |
| CN109136198B (en) | A live vector vaccine of recombinant fowl pox virus expressing chicken infectious anemia virus VP1 and VP2 genes | |
| Ennaji et al. | Infectious bronchitis virus in poultry: Molecular epidemiology and factors leading to the emergence and reemergence of novel strains of infectious bronchitis virus | |
| WO2021103421A1 (en) | Gene vii type newcastle disease virus attenuated strain and use thereof | |
| CN112779193B (en) | Virulent strain of mycoplasma synoviae and application thereof | |
| CN108728419A (en) | Express aviadenovirus penton Protein reconstitutions newcastle disease vaccine Candidate Strain rAI4-penton and construction method | |
| CN113122509A (en) | Infectious laryngotracheitis virus virulent strain and application thereof | |
| CN118222521B (en) | Preparation and application of newcastle disease virus recombinant attenuated strain and vaccine | |
| Mahamud et al. | Efficacy of genotype-matched Newcastle disease virus vaccine formulated in carboxymethyl sago starch acid hydrogel in chickens vaccinated via different routes | |
| CN109402065B (en) | Muscovy duck subtype C avian metapneumovirus attenuated strain and preparation and application thereof | |
| CN107158369B (en) | Vaccine prepared by using constructed gene VII type newcastle disease virus attenuated strain | |
| CN114395536B (en) | Avian adenovirus type 4, 8 and 11 trivalent vaccine and preparation method and application thereof | |
| CN119372158B (en) | Recombinant HVT co-expressing H9 subtype AIV HA gene, IBV S gene and IBDV VP2 gene and its application | |
| CN107213460B (en) | Gene VII type newcastle disease vaccine | |
| KR101102271B1 (en) | Attenuated Chicken Infectious Bronchitis Virus and Chicken Infectious Bronchitis Vaccine | |
| CN109628412B (en) | A chicken infectious bronchitis virus strain and its application | |
| Ren et al. | Genotype-matched recombiant inactivated Newcastle disease virus vaccine confer protection against genotype Ⅻ challenge in geese with maternal antibodies | |
| CN107058244B (en) | Gene VII type newcastle disease virus low virulent strain constructed by P protein mutation | |
| JPH10179144A (en) | Non-toxic Mycoplasma synoviae and its vaccine | |
| CN110499296A (en) | A heat-resistant serotype 8b avian adenovirus genetic engineering vaccine candidate strain and its construction method | |
| CN105087502B (en) | H9N2 subtype avian influenza virus temperature sensitivity attenuated live vaccine Candidate Strains CA 28（AH）And its application | |
| WO2014061914A1 (en) | Infectious bronchitis virus k40/09 strain, and vaccine for infectious bronchitis using same | |
| CN110713987B (en) | Recombinant gene VII type Newcastle disease virus strain and vaccine composition, preparation method and application thereof | |
| KR100913425B1 (en) | Influenza Virus and Immunogenic Compositions Comprising the Same | |
| CN106754744B (en) | Group I avian adenovirus strain of serum type 4 and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |